← All trials
NCT04410406
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2020
- Primary completion
- Sep 1, 2022
- Completion date
- Sep 1, 2023
- First posted
- Jun 1, 2020
- Last posted
- Jun 1, 2020
- Enrollment
- 250
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Washington University in St. LouisLead sponsor
- Case Western Reserve UniversityCollaborator
- Case Western Reserve UniversityOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Regional Hospital of Agboville, Southern Cote d'IvoireCollaborator
- Regional Hospital of Agboville, Southern Cote d'IvoireOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.